Agilent Technologies (Oligo GMP) vs Curia (RNA/Advanced): CDMO Comparison
How does Agilent Technologies (Oligo GMP) compare to Curia (RNA/Advanced) for Oligo/ASO manufacturing?
Side-by-side comparison of Agilent Technologies (Oligo GMP) and Curia (RNA/Advanced) on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Curia (RNA/Advanced) holds 18 active EMA GMP certificates; Agilent Technologies (Oligo GMP) does not appear in EudraGMDP.
On a 13-modality CDMO landscape, both Agilent Technologies (Oligo GMP) and Curia (RNA/Advanced) qualify as Oligo/ASO manufacturers; Curia (RNA/Advanced) carries the higher composite Signal Score for Oligo/ASO programs in this comparison.
What to evaluate for Oligo/ASO programs
Both Agilent Technologies (Oligo GMP) and Curia (RNA/Advanced) qualify as Oligo/ASO CDMOs. When choosing between them for Oligo/ASO programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Synthesis scale
Match synthesizer scale (mmol to mol) to your clinical and commercial demand, and confirm the CDMO can scale without shifting the impurity profile.
Chemistry & conjugation
Confirm experience with your backbone and modifications (phosphorothioate, 2'-MOE/F) and any conjugation (GalNAc, lipid) your molecule requires.
Purity & analytics
Full-length product, deletion/addition impurities, and residual metals drive release. Look for established orthogonal analytics.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: Agilent Technologies (Oligo GMP) vs Curia (RNA/Advanced)
How does Agilent Technologies (Oligo GMP) compare to Curia (RNA/Advanced) for Oligo/ASO manufacturing?
On CDMO Signal's composite Signal Score, Agilent Technologies (Oligo GMP) is 74/100 and Curia (RNA/Advanced) is 79/100; Agilent Technologies (Oligo GMP) has 2 FDA inspections on record vs 2 for Curia (RNA/Advanced); European coverage is 0 active EMA+MHRA certificates for Agilent Technologies (Oligo GMP) vs 18 for Curia (RNA/Advanced). Both are tracked in the CDMO Signal directory as Oligo/ASO CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Agilent Technologies (Oligo GMP) or Curia (RNA/Advanced)?
Both Agilent Technologies (Oligo GMP) and Curia (RNA/Advanced) maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Agilent Technologies (Oligo GMP) has 2 FDA inspections on record; Curia (RNA/Advanced) has 2.
How do Agilent Technologies (Oligo GMP) and Curia (RNA/Advanced) compare on European GMP coverage?
Agilent Technologies (Oligo GMP) holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Curia (RNA/Advanced) holds 18 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Agilent Technologies (Oligo GMP) or Curia (RNA/Advanced)?
Agilent Technologies (Oligo GMP) is matched to 1 ClinicalTrials.gov record as a manufacturing partner; Curia (RNA/Advanced) is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Oligo/ASO manufacturing — Agilent Technologies (Oligo GMP) or Curia (RNA/Advanced)?
Both Agilent Technologies (Oligo GMP) and Curia (RNA/Advanced) are tagged as Oligo/ASO CDMOs in our directory, so both are credible options for Oligo/ASO programs. The most important differentiator for Oligo/ASO selection is typically synthesis scale: Match synthesizer scale (mmol to mol) to your clinical and commercial demand, and confirm the CDMO can scale without shifting the impurity profile. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →